Dependence of cytokine concentration in coproextracts in children with inflammatory bowel diseases on disease activity

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) affect more than 6.8 million people. The key factor in the immunopathogenesis of these diseases is the intestinal wall infiltration by various immunocompetent cells and their proinflammatory cytokine production.

AIM: To compare the levels of 14 cytokines in the coproextracts of patients with IBD with various disease activities.

MATERIALS AND METHODS: The examined cohort comprised 30 children with CD, 33 with UC, and 20 healthy children (control group). UC and CD were diagnosed based on generally accepted clinical and endoscopic criteria. The concentrations of 14 cytokines (IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, and TNF) in aqueous-salt coproextrates were determined using the multiplex method (MagPix, BioRad, USA).

RESULTS: The levels of all studied cytokines were significantly increased in all sick children, even in remission, compared with the control group. The concentration of proinflammatory cytokines (TNF, IL-1β, IL-6, IL-17A, and IL-17F) consistently decreased with the decrease in disease activity in the coproextracts of patients with CD and UC. Furthermore, the IL-22, IL-33, and IL-10 levels increased as the inflammation activity decreased.

CONCLUSIONS: The lack of normalization of cytokine levels in remission raises the question of the need for further study of IBD immunopathogenesis and the search for new therapeutic approaches.

Keywords

cytokines / Crohn’s disease / ulcerative colitis / inflammatory bowel disease

References

[1] Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5–17. doi: 10.1016/j.cyto.2014.09.011

[2] Raphael I., Nalawade S., Eagar T.N., Forsthuber T.G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases // Cytokine. 2015. Vol. 74, N. 1. P. 5–17. doi: 10.1016/j.cyto.2014.09.011

[3] Cao H, Diao J, Liu H, et al. The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2023;29(5):818–829. doi: 10.1093/ibd/izac199

[4] Cao H., Diao J., Liu H., et al. The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases // Inflamm Bowel Dis. 2023. Vol. 29, N 5. P. 818–829. doi: 10.1093/ibd/izac199

[5] Ghilas S, O’Keefe R, Mielke LA, et al. Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease. Front Immunol. 2022;13:944982. doi: 10.3389/fimmu.2022.944982

[6] Ghilas S., O’Keefe R., Mielke L.A., et al. Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease // Front Immunol. 2022. Vol. 13. P. 944982. doi: 10.3389/fimmu.2022.944982

[7] Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells. 2021;10(1):111. doi: 10.3390/cells10010111

[8] Mahapatro M., Erkert L., Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut // Cells. 2021. Vol. 10, N 1. P. 111. doi: 10.3390/cells10010111

[9] Katsandegwaza B, Horsnell W, Smith K. Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease. Int J Mol Sci. 2022;23(16):9344. doi: 10.3390/ijms23169344

[10] Katsandegwaza B., Horsnell W., Smith K. Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease // Int J Mol Sci. 2022. Vol. 23, N 16. P. 9344. doi: 10.3390/ijms23169344

[11] Toptygina AP, Semikina EL, Bobyleva GV, Miroshkina LV, Petrichuk SV. Cytokine profile in children with inflammatory bowel disease. Biochemistry. 2014;79(12):1673–1679. (In Russ). EDN: TQQMVZ

[12] Топтыгина А.П., Семикина Е.Л., Бобылева Г.В., Мирошкина Л.В., Петричук С.В. Цитокиновый профиль у детей с воспалительными заболеваниями кишечника // Биохимия. 2014. T. 79, № 12. C. 1673–1679. EDN: TQQMVZ

[13] Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13(12):1174–1181. doi: 10.1016/j.autrev.2014.08.019

[14] Singh R.P., Hasan S., Sharma S., et al. Th17 cells in inflammation and autoimmunity // Autoimmun Rev. 2014. Vol. 13, N 12. P. 1174–1181. doi: 10.1016/j.autrev.2014.08.019

[15] Zhao J, Lu Q, Liu Y, et al. Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies. J Immunol Res. 2021;2021:8816041. doi: 10.1155/2021/8816041

[16] Zhao J., Lu Q., Liu Y., et al. Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies // J Immunol Res. 2021. Vol. 2021. P. 8816041. doi: 10.1155/2021/8816041

[17] Toskas A, Milias S, Delis G, et al. Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study. Diagnostics. 2023;13(13):2185. doi: 10.3390/diagnostics13132185

[18] Toskas A., Milias S., Delis G., et al. Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study // Diagnostics. 2023. Vol. 13, N 13. P. 2185. doi: 10.3390/diagnostics13132185

[19] Zorzi F, Monteleone I, Sarra M, et al. Distinct profiles of effector cytokines mark the different phases of Crohn’s disease. PLoS ONE. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562

[20] Zorzi F., Monteleone I., Sarra M., et al. Distinct profiles of effector cytokines mark the different phases of Crohn’s disease // PLoS ONE. 2013. Vol. 8, N 1. P. e54562. doi: 10.1371/journal.pone.0054562

[21] Shohan M, Dehghani R, Khodadadi A, et al. Interleukin-22 and intestinal homeostasis: Protective or destructive? IUBMB Life 2020;72(8):1585–1602. doi: 10.1002/iub.2295

[22] Shohan M., Dehghani R., Khodadadi A., et al. Interleukin-22 and intestinal homeostasis: Protective or destructive? // IUBMB Life 2020. Vol. 72, N 8. P. 1585–1602. doi: 10.1002/iub.2295

[23] Monticelli LA, Osborne LC, Noti M, et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA. 2015;112(34):10762–10767. doi: 10.1073/pnas.1509070112

[24] Monticelli L.A., Osborne L.C., Noti M., et al. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions // Proc Natl Acad Sci USA. 2015. Vol. 112, N 34. P. 10762–10767. doi: 10.1073/pnas.1509070112

[25] Mantani PT, Vallejo J, Ljungcrantz I, et al. Interleukin-25 reduces Th17 cells and inflammatory responses in human peripheral blood mononuclear cells. Hum Immunol. 2018;79(9):685–692. doi: 10.1016/j.humimm.2018.06.008

[26] Mantani P.T., Vallejo J., Ljungcrantz I., et al. Interleukin-25 reduces Th17 cells and inflammatory responses in human peripheral blood mononuclear cells // Hum Immunol. 2018. Vol. 79, N 9. P. 685–692. doi: 10.1016/j.humimm.2018.06.008

[27] Fina D, Franzè E, Rovedatti L, et al. Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut. Mucosal Immunol. 2011;4(2):239–244. doi: 10.1038/mi.2010.68

[28] Fina D., Franzè E., Rovedatti L., et al. Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut // Mucosal Immunol. 2011. Vol. 4, N 2. P. 239–244. doi: 10.1038/mi.2010.68

[29] Su J, Chen T, Ji XY, et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in flammatory bowel disease. Inflamm Bowel Dis. 2013;19(4):720–728. doi: 10.1097/MIB.0b013e3182802a76

[30] Su J., Chen T., Ji X.Y., et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in flammatory bowel disease // Inflamm Bowel Dis. 2013. Vol. 19, N 4. P. 720–728. doi: 10.1097/MIB.0b013e3182802a76

RIGHTS & PERMISSIONS

Toptygina A.P., Semikina E.L., Tsvetkova V.S., Krasnovidova A.E., Potapov A.S.